
The Fragrance Market's Squeezed Middle
But in May, the 17-year-old brand decided that upmarket was the way to move, wiping its Instagram feed clean and replacing it with its new Voyages collection of fine perfumes sold for $250 at Harrods and Bergdorf Goodman. The accompanying campaign, shot by photographer Nick Knight, lends it a higher-fashion positioning than past products. Knight told The Business of Beauty he spent four weeks photographing the fragrances with the goal 'to create images that live in your memory and your emotions.'
Nest CEO Edgar Huber, who joined the brand in March 2023, said, 'One of the key elements we have identified for us is really to elevate the brand, make the brand more sophisticated, modernize it, [and make] it more attractive on a global basis.' Still, the body sprays are staying put at Ulta Beauty, and its core sub-$200 range of fragrances is remaining in retailers like Sephora.
At first glance, this low-to-high oscillation might seem chaotic, especially in context: Nest's beloved founder Laura Slatkin announced her departure from day-to-day activities earlier in the month in the midst of its rebranding. But consumer desire for affordable scents you can layer and ultra-luxury fragrances that are cult-worthy reflect the current state of the fragrance market: price points low and high are booming, while prestige sales are lagging.
ADVERTISEMENT
According to data from Circana, sales of fragrances with an average price under $50 grew by 11 percent in the first quarter of this year, while those over $150 increased by 14 percent. The accessible spray categories continue to skyrocket, with body spray sales doubling their sales and hair perfumes up 70 percent. The $50 to $150 range, however – where the smaller sizes of classic icons like Chanel No. 5 and Miss Dior sit — has seen sales decline 3 percent.
'After Covid, niche kind of exploded,' said fragrance consultant Robert Sorce, a former president of Byredo who has also worked at Creed and Amouage. 'A lot of prestige brands are thinking, 'How do I really upscale to compete with those niche brands?''
Brands with products in the mid-price range — which is where Nest's core fragrances land, at $102 — have several challenges when expanding to both the high and the accessible ends of the spectrum. Both require a calibration of brand equity, whether that means elevation to support fine fragrance launches or preservation when going downmarket.
Nest's revamp strategy has gone beyond an Instagram reset and high-end campaign. Behind the scenes, it has meant 'closing distribution we didn't want to have,' including combating third-party marketplace sellers on Amazon, as well as reducing discounts and promotions, said Huber. In addition, the brand has pursued more 'consistent and coherent brand expression' with packaging redesign.
Stretching the Limits
With the continuous popularization of niche fragrances well above the $250 price range, the price of what qualifies as 'luxury' fragrance has shifted far upward. The sub-$200 fragrances, typically designer in nature, feel inexpensive compared to niche labels pushing the boundaries of what fragrance collectors are willing to pay.
'The prices just keep going up,' said Sorce. Kering-owned Creed's 100 mL signature Aventus fragrance has climbed above $500, while Maison Francis Kurkdjian's Baccarat Rouge retails at $335 for 50 mL. Brands such as Roja can sell bottles over $3,300.
The number of luxury fashion brands with upmarket fragrance offerings has steadily risen in recent years. Following Dior's La Collection Privée ($220 for the smallest size) and Chanel's Les Exclusifs de Chanel ($350), which debuted in the 2000s, Gucci came out with its Alchemist's Garden line ($280 to $415) in 2019 and Louis Vuitton launched its Les Extraits in 2021 ($585). Luxury fashion brands entering or restarting fragrance have skipped over the prestige category entirely and gone straight to luxury, such as Puig-owned Dries Van Noten with its collection ranging from $310 to $365 and Kering-owned Bottega Veneta's Colpo di Sole fragrance at $450. Even premium brands have climbed up, with Diptyque launching Les Essences de Diptyque ($330) last year.
'They saw this surge in niche and that people were paying for $500 for a bottle of Creed,' said Sorce. 'They were like, 'There's no price resistance, so we're going to cut out the bottom. It makes more sense to just invest more in the top.''
ADVERTISEMENT
For Nest, the reasons to go upmarket were numerous, said Huber. He noted that luxury is the 'fastest growing sub-category of fine fragrances,' and has global appeal – while body sprays are a very North America-centred phenomenon. The new line will help the brand's goal of moving further into luxury retailers in Europe and the Middle East, he said.
Margins are also better on fine fragrances, even with the higher cost of luxury ingredients, said Sorce.
The High-Low Shopper
While a highly concentrated eau de parfum with an expensive campaign is one of the only ways perfumiers can go upmarket, there are nearly infinite ways to go more accessible. In addition to less concentrated options like body sprays and hair perfumes, minis, rollerballs, and 'ancillaries' like lotions are all seeing high demand. These launches are still coming in rapid succession, with Boy Smells and By Rosie Jane both being the latest to join the body spray craze last week.
'I'm a prestige value shopper. I love beautiful products, but I also want to have an attainable price point that doesn't feel like a luxury,' said By Rosie Jane founder Rosie Jane Johnston, who launched a fragrance-forward body care collection in May.
The most obvious customer for these launches is the entry-level shopper, which is as young as Gen Alpha, thanks to Sol de Janeiro. According to Huber, 64 percent of Nest's body mist customers are new to the brand, creating a ladder for shoppers who might upgrade to the core fragrances and Voyages eventually.
More than ever, it appears masstige, premium and luxury brands are finding common ground, creating cheaper formats or ultra-luxe options. Few, however, are revitalizing their core segments.
But the premium price range slump isn't affecting all brands equally, as popular designer perfume franchises remain resilient: LVMH listed Dior's J'adore as one of its scents with 'enduring appeal' in its first-quarter 2025 earnings report. Buzzy scents like Glossier You have won over TikTok and brought newness to the classic category.
As more luxury brands like Balenciaga plan their entries and re-entries into fragrance, it's unlikely that new launches will be in the $100 price range, according to Sorce. 'They'll look at more of the $200-and-above range,' he predicted.
Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
6 minutes ago
- CNBC
AstraZeneca CEO doubles down on U.S. amid rumors of listing shift
AstraZeneca CEO Pascal Soriot on Tuesday reiterated the pharmaceutical firm's commitment to the U.S. market amid reports that he is considering shifting its listing stateside. Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was "rapidly transferring manufacturing" across the Atlantic so it could serve all U.S. patient needs domestically. "We have lots of reasons to be here [in the U.S.]," Soriot told media during an earnings call. "This country [the U.S.] will represent, we hope, 50% of our revenue by 2030. We have thousands of employees … across the country," he added. AstraZeneca has been doubling down on the U.S. market, saying in its second-quarter earnings report on Tuesday that the country was key to its ambition of delivering $80 billion in revenue by the end of the decade. "We are a global company but we are certainly, very much, present and rooted in the U.S.," Soriot said, noting that it plans to soon become self-sufficient there. The company said last week it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities. It marks the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs and calls by President Donald Trump to reshore manufacturing. "Our investment is reflecting our belief in the growth of this country. We want to contribute to this," Soriot said, noting that he had met with the Trump administration to discuss growth plans within the sector. "The U.S. really leads in biopharmaceutical innovation these days," he added, criticizing Europe's failure to drive development. "Today, very little comes out of Europe." AstraZeneca, which made international headlines by developing one of the key Covid-19 vaccines, has long been prioritizing the U.S. market. The U.S. accounted for over 40% of the company's annual revenues in 2024. Earlier this month, The Times reported that the firm may move its listing from London to the U.S., in what analysts said would be a major blow to the U.K.'s public markets. AstraZeneca at the time declined to comment on the report. However, chief financial officer Aradhana Sarin said Tuesday that the company remains "committed" to the U.K. It comes as AstraZeneca posted better-than-expected second-quarter earnings on Tuesday, driven by demand for key cancer and biopharmaceutical products. The Anglo-Swedish pharma firm posted revenues of $14.46 billion over the three-month period to June 30, ahead of the $14.07 billion estimated by analysts in an LSEG poll. Quarterly adjusted core operating profit came in at $4.58 billion versus $4.48 billion anticipated. The FTSE 100 company maintained its full-year forecast for revenues to rise by a high single-digit percentage and core earnings per share to increase by a low double-digit percentage. It comes as the European pharmaceutical sector is facing anticipated levies of 15% on imports to the U.S. as part of a broader EU-U.S. trade deal. Analysts warned that the tariffs, if levied at 15% or above, could hamper European firms and the bloc's broader economy. AstraZeneca nevertheless suggested in April that it would maintain its 2025 sales guidance if U.S. tariffs on European pharma products came in in line with those levied against other sectors. "This issue of tariffs is not really an issue that is affecting us very much," Soriot said.


Business Journals
6 minutes ago
- Business Journals
Supply chain visualization in the absence of crystal balls
Ira Kalish, Chief U.S. Economist, Deloitte, recently noted to colleagues that somewhat predictable, precedent-guided variables in economic models make for more informed predictions. For many watching economic forecasts, the value of these predictable variables may be most evident when there are suddenly less available. Anyone leading a business – big or small – is familiar with watching and managing numerous variables, and likely grateful for some level of predictability and the measurable metrics that go a long way in providing clarity, particularly in supporting supply chain planning during a time of economic uncertainty. Supply chain woes have been a recurring theme for a while, during the COVID-19 pandemic and now with current market volatility. Given the new normal of unpredictability in this space, I've checked in with colleagues on the fundamentals that can help leaders steering complex organizations as nimbly as possible through related surprises. Import-Export in Massachusetts The general public may have eyes on finished consumer goods availability and pricing, but Massachusetts import and export activity is foundational to the local manufacturing sector supply chain for numerous industries. Massachusetts' manufacturing supply chain contributes $61.9 billion to the state economy, employs over 230,000 people across more than 6,000 firms, and is driven by high-tech sectors like medical devices and advanced materials.[1] Related structural investment is of note. In 2024, the Healey-Driscoll administration and MassTech Collaborative's Center for Advanced Manufacturing worked to strengthen supply chains and encourage sector growth with more than $3.5 million in grants to 23 manufacturing companies through the Massachusetts Manufacturing Accelerate Program (MMAP).[2] Also in 2024, Massachusetts invested $100 million in upgrading ports and maritime infrastructure to support clean energy development and enhance supply chain logistics, especially for manufacturing sectors reliant on imported components and offshore shipment capacity.[3] Nearshoring or not: integrated systems can reduce variables Work is ongoing to optimize import and export success, yet economic forces may drive organizations to create their own supply chain stability by reshoring in the United States. Nearshoring may appear to be a logical reflex response, and there are reasons why it could be strategic for some. 'Economically viable opportunities for reshoring production to the U.S. are likely to be higher-value, complex products with strict quality standards, produced with technologically advanced, higher-capital intensity processes,' noted Kate Hardin, managing director, Deloitte Services LP and executive director at Deloitte's Research Center for Energy & Industrials. Nearshoring may offer a more nimble approach to production scenario planning, but there are other factors that can offer agility. For example, factories using sensors can enable digital supply chains to benefit from AI algorithms that offer insights and support prediction, reaction and integration. The evolution of this automated process is creating greater resilience overall, as variables can be addressed in the moment – particularly for those that have greater challenges than sourcing alone. Connecting supply chain aspects Availability of raw materials or finished goods deserves the spotlight at this time. Risk management has long included diversifying suppliers, increasing inventory buffers and developing contingency plans. Life sciences companies often need to go beyond this to accommodate a broad scope of related issues such as evolving regulatory standards compliance, including adhering to guidelines for the transportation and storage of pharmaceuticals. Transparency, traceability and efficiency can play a crucial role in the timely delivery of materials; digital transformation including AI, machine learning and blockchain technology may play a role in this process. An example of this is Deloitte's work with a cell and gene therapy (CGT) company. These therapies often involve living cells, which require precise handling, storage, and transportation conditions to maintain their viability and effectiveness. Any disruption or delay in the supply chain can compromise the quality of the therapy, leading to potential treatment failures and significant financial losses. Even without the current supply chain volatility, a smooth and uninterrupted flow of product involves rigorous planning and execution. One way that Deloitte moved to support this is through ConvergeHEALTH™ CGT Vantage, a software-as-a-service solution designed to simplify the orchestration of CGTs with clear visibility into chain of identity (COI) and chain of custody (COC) across industry stakeholders. The system offers a single portal point of connection for patient treatments regardless of therapy or manufacturer, and provides CGT innovators with supply chain transparency on product launch and go-to market while safely managing COI and COC. Navigating a web of production considerations As the CGT example shows, supply chain management can be an interconnected web of touch points originating with sourcing. In line with that, I'll close with some leading practices to consider: Apply duty deferral, reduction, and duty recovery strategies Explore the use of foreign trade zones, bonded warehouses and other bonded regimes, Chapter 98 provisions in the United States, and drawback opportunities Seek exemptions and exclusions: If available, participate in public comment and hearing processes, and pursue available exemptions and exclusions Strategically re-evaluate supply networks and structures such that resiliency and agility is embedded in the system vs. managed outside the system Study methods to reduce customs values, such as working to unbundle fees from product prices to remove non-dutiable elements, assessing/implementing First Sale for Export structures, and joining reconciliation programs for customs value declarations and duty/tariff payment management Supply chain management is a vast undertaking with numerous variables that stretch from tariff-related planning to larger structural assessments. If you are working through these challenges to visualize and improve your process and want to connect, please reach out to me at officeofrebeccachasen@ Deloitte may have subject matter specialists that can help. This article contains general information only and Deloitte is not, by means of this article, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This article is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional adviser. Deloitte shall not be responsible for any loss sustained by any person who relies on this article. About Deloitte Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ('DTTL'), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as 'Deloitte Global') does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the 'Deloitte' name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see to learn more about our global network of member firms.


New York Post
36 minutes ago
- New York Post
Why Erin Andrews and Charissa Thompson kept silent on Taylor Swift-Travis Kelce trip
Taylor Swift and Travis Kelce's love story is theirs to tell. That's the message pals Erin Andrews and Charissa Thompson drove home Monday on the latest installment of their 'Calm Down' podcast, days after the Chiefs tight end posted a handful of Instagram photos of the group's offseason getaway with the pop superstar. 'When the opportunity came about for all of us to spend time together and go on vacation, we were elated to have time with them, but also, just in general, see what she's all about,' Thompson said of Swift, who has been dating Kelce for two years. Advertisement 3 Travis Kelce and Taylor Swift spent time with Charissa Thompson and Erin Andrews this offseason. Travis Kelce/Instagram 3 The couple has been dating since 2023. Travis Kelce/Instagram 'She's everything and more. Their lives are so public, so it was very important for Erin and I not to say anything — not because we don't like to share stuff with you, but it's important for us to let them dictate the narrative on things they do in their personal life.' Advertisement Thompson, a longtime Swiftie like Andrews, added the 14-time Grammy winner is 'a dream,' and she's elated the couple 'make[s] each other happy.' Kelce, 35, who reported to training camp this month ahead of his 13th NFL season, sent the internet into a frenzy on July 24 when he posted pics of his offseason 'adventures' with Swift, 35, Andrews, Thompson and their significant others, Jarret Stoll and Steve Cundari, respectively. 3 Travis Kelce is currently preparing for his 13th season in the league. Travis Kelce/Instagram 'We're so protective of them and their privacy and what they deserve, so that's why we never said anything or never planned on saying anything,' Andrews added on Monday's episode. Advertisement '… I will say this, our group, the six of us, we had a time.' Andrews, 47, and Thompson, 43, have long championed a Kelce-Swift connection, with the Fox Sports reporters encouraging the 'Fortnight' singer to give the three-time Super Bowl winner a chance after he failed to pass along a friendship bracelet at a July 2023 Eras Tour show with his telephone number on it. Swift made her first appearance at a Chiefs game two months after Kelce's reveal.